Search This Blog

Saturday, December 19, 2020

FibroGen’s action date for Roxadustat postponed

 

  • FibroGen (NASDAQ:FGEN) announced that the FDA has extended the review period of its NDA for Roxadustat by three months, with an updated action date set for March 20.
  • In February, the company announced that the FDA accepted the NDA for Roxadustat in the treatment for anemia of chronic kidney disease. The PDUFA date was scheduled for December 20.
  • The review is in the final stages and has required an extension of the action date as the company submits additional analyses of existing clinical data for Roxadustat, FibroGen said in the announcement.
  • The first in a new class of medicines called HIF-PH inhibitors that promotes erythropoiesis, Roxadustat has already been approved in China, Japan, and Chile for anemia of CKD in adults, and the marketing application for the therapy is also under review in Europe.
  • For the development and commercialization of Roxadustat as a potential treatment for anemia, AstraZeneca (NASDAQ:AZN) has partnered with FibroGen for the regions including U.S., China, other markets in the Americas, while Astellas Pharma (OTCPK:ALPMF) is collaborating for Europe and Japan.
  • Ahead of the announcement, FibroGen fell sharply in post-market trading on Friday.
  • https://seekingalpha.com/news/3646024-fibrogen-s-action-date-for-roxadustat-postponed

UK says new coronavirus strain is more infectious, but vaccines should still work

 A new strain of coronavirus identified in the United Kingdom is up to 70% more infectious but it is not thought to be more deadly and vaccines should still be effective, Prime Minister Boris Johnson and scientists said on Saturday.

Johnson and England’s Chief Medical Officer Chris Whitty said the variant strain had been discovered through Public Health England’s genomic surveillance and it was now confirmed that it spread more easily that the original version.

“There’s no evidence that it causes more severe illness or higher mortality, but it does appear to be passed on significantly more easily,” Johnson told a news conference to announce tougher lockdown restrictions for millions of people.

“Although there’s considerable uncertainty, it may be up to 70% more transmissible than the old variant, the original version of the disease. This is early data and it’s subject to review.

“But it’s the best that we have at the moment and we have to act on information as we have it, because this is now spreading very fast.”

Cases in Britain have soared in the last two weeks, and were rising fast, data showed.

Britain’s Chief Scientific Adviser Patrick Vallance said COVID-19 vaccines appeared to be adequate in generating an immune response to the variant of the coronavirus.

“We think it (the variant) may be in other countries as well,” Vallance told reporters. “It may have started here, we don’t know for sure.”

Vallance said in parts of England, including London, the south east and east of England, the new variant was becoming the dominant form.

“This virus has taken off,” he said of the mutation. “It’s moving fast and it’s leading inevitably to a sharp increase in hospital admissions.”

“There is no evidence it causes a more severe disease, causes more hospitalisation, causes more trouble than the other virus, it basically looks similar.”

https://www.reuters.com/article/health-coronavirus-britain-strain/update-1-uk-says-new-coronavirus-strain-is-more-infectious-but-vaccines-should-still-work-idUSL1N2IZ0DM

Stryker, Zimmer shift strategies to capitalize on growing ambulatory market

 The shift of procedures from the hospital to outpatient settings has gained momentum in recent years as commercial insurers boosted coverage and surgeons warmed to the idea of treating patients in ambulatory surgery centers. 

Now that Medicare is catching up to this trend, experts expect the outpatient procedure migration to speed up with medical device companies like Stryker and Zimmer Biomet looking to capitalize on this shift, particularly in the orthopaedic space.

Bain & Company in a 2019 report projected the percentage of hip procedures in ASCs to grow from just over 9% to 25% by the mid-2020s and knee procedures to grow from 10% to 30%.

While hospitals have opposed the moves, in part citing safety risks, Medicare seems to agree.

CMS recently finalized a Medicare rule that moved 11 services onto the ASC covered procedures list, including total hip replacements. The agency also finalized new criteria for the covered procedures list, which will cover about 267 musculoskeletal-related services when conducted in outpatient settings. In addition, CMS finalized a three-year phase-out plan of the inpatient-only list.

Stryker has been looking to capitalize on the movement of surgeries as it has been accelerating over the last decade or so.

"This is definitely the continuation of a trend that started long ago, and we anticipate will continue well into the future," said Nate Miersma, Styker's senior director of ASC.

All of these moves continue CMS' embrace of outpatient care, which the agency says can help lower overall healthcare costs while maintaining the same level of safety as an inpatient setting.

Analysts with Moody's Investors Service wrote in a recent report that the final rule will ultimately "drive more highly profitable orthopedic procedures out of hospital inpatient settings."

Miersma would not project exact figures for the anticipated growth of total hip procedures in ASCs, but said that Stryker expects the volume of purchases to increase due to CMS' rule, much like what happened when the agency made the same coverage change for total knee replacements.

Stryker now expects spine procedures to follow total hip replacements, Miersma added.

Even without Medicare coverage, the percentage of spine procedures conducted in ASCs is projected to grow from 7% in 2015 to about 30% by the mid-2020's, according to the Bain report.

Warming up to ASCs

Bill Prentice, CEO of the trade group Ambulatory Surgery Center Association, said that procedures like total knee and hip replacements have been covered by commercial insurers for several years, but CMS has dragged its feet in embracing ASCs.

Prentice was a bit warier of a boom in procedures due to CMS opening up coverage policies, but he did predict a "steady progression" of procedures moving from inpatient to outpatient settings due to the agency's changes.

Stryker CEO Kevin Lobo once spoke of ASCs as a risky area, according to Miersma. However, he added that Lobo now sees ASCs as a "great opportunity."

https://www.healthcaredive.com/news/device-companies-focusing-on-growing-ASC-market/592297/

HHS starts doling out $25B in third phase of CARES provider funding

 

  • HHS began distributing the third phase of COVID-19 relief funding for providers Wednesday, with $24.5 billion to go to more than 70,000 providers through the end of January.
  • The amount exceeds the original $20 billion planned for this tranche as officials realized more would be needed to get providers close to whole from coronavirus-related losses. HHS said up to 88% of applicants' reported losses are being reimbursed.
  • This phase opened applications up to providers who had previously received, or been rejected for, provider relief funds as well as behavioral health providers and those who began practicing between January and March of this year.

The funding announcement comes as Congress debates another COVID-19 relief bill, which could include additional money for providers. A bipartisan proposal put forward last week was endorsed by Democratic leadership and talks have continued this week. 

It allocates another $35 billion for the Provider Relief Fund created by the Coronavirus Aid, Relief, and Economic Security Act passed in March. Congress allocated $175 billion to providers for the tranche in multiple pieces of legislation.

The first phase of $50 billion went broadly to Medicare fee-for-service providers in April in an attempt to get money out the door as quickly as possible. The $18 billion second phase required applications, and made Medicaid providers and dentists also eligible. It began distribution in June.

The PRF has also allocated money specifically for rural hospitals ($11.3 billion), facilities in high-impact areas ($22 billion), safety net hospitals ($12 billion) and nursing facilities ($7.4 billion). That leaves less than $30 billion not yet allocated.

While providers have said the funds are sorely needed to help them continue to operate, the funding distribution has encountered some criticism. Larger hospitals got significant funds and have in some cases still performed relatively well financially.

Operator HCA Healthcare, for example, wound up returning all $6 billion of the CARES funding and advanced Medicare payments it received.

There has also been frustration with some of the reporting requirements imposed on those applying for and receiving the money, although HHS rolled back one regulation considered among the most difficult.

https://www.healthcaredive.com/news/hhs-starts-doling-out-25b-in-third-phase-of-cares-provider-funding/592312/

Should you avoid alcohol when getting a coronavirus vaccine?

 Drinking alcohol after getting a coronavirus vaccine can significantly blunt the immune response and potentially render the vaccine ineffective, according to a leading Russian scientist. “We strongly recommend refraining from alcohol for three days after each injection,” Alexander Gintsburg, head of the Gamaleya National Center of Epidemiology and Microbiology in Moscow, which is developing the Sputnik V vaccine, told New Scientist.

This warning doesn’t just apply to the Sputnik V vaccine, but all covid-19 vaccines and indeed all other vaccines. “This is quite obvious,” he said.

Existing scientific literature on alcohol and the immune system shows that excess alcohol is an immunosuppressant so people who drink a lot are more susceptible to infections. “Heavy drinkers have many problems and poor immune function is one of them,” says immunologist Eleanor Riley at the University of Edinburgh, UK.

In trials, about 10 per cent of people don’t become immune after receiving the Sputnik V vaccine and the figure is similar for other vaccines. The reasons for this are unknown. Whether alcohol could be a factor hasn’t been investigated.

2012 study by researchers in Sweden found that low-to-moderate alcohol consumption slightly suppressed the inflammatory response to a vaccine against bacterial pneumonia, but had no impact on the immune response. The researchers defined this level of alcohol consumption as an average intake of less than 30 grams a day, about the same as three vodkas.

Gintsburg said that drinking 300 grams of vodka – about 12 UK measures, which contain a total of about 120 grams of alcohol – suppresses antibody production. But one glass of champagne would be OK, he said.

This week, Anna Popova, the head of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), sparked a controversy in Russia  when she advised Russians to quit drinking alcohol two weeks before their first vaccine shot and for a further three weeks after the second. There is a three-week gap between injections so that is a total of eight weeks on the wagon.

Gintsburg told New Scientist that this was too stringent. “Of course, we are not talking about a complete ban on alcohol during vaccination. This is just a reasonable limitation of consumption until the body has formed its own immune response to coronavirus infection,” he said. “It is important to understand that excessive alcohol consumption can significantly reduce immunity and therefore reduce the effectiveness of vaccination or even make it meaningless. Moreover, this is true not only for Sputnik V, but also for any other vaccine.”

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, which is funding the Sputnik V programme, says: “It applies to all vaccines, there is nothing particular about Sputnik vaccine that makes it more prone to alcohol consumption.”

Some people might want to err on the side of caution, says Paul Klenerman at the University of Oxford. “There’s no doubt that chronic excess alcohol has a significant impact on many aspects of immunity,” he says. “What isn’t clear is whether just a small amount would have any significant effect in [real-life settings]. So it is plausible and you could simply be very cautious and say avoid it. Different countries might end up giving different guidance.”

New Scientist made contact with a volunteer on the UK arm of the trial of the vaccine being developed by AstraZeneca and the University of Oxford. There was no instruction to abstain from alcohol around the time of vaccination, the volunteer said.

A volunteer on the UK-based Imperial College London vaccine clinical trial also said there was no requirement to avoid alcohol. However, an information sheet given to trial participants says that people with “suspected or known current alcohol or drug dependency” cannot take part in the study. It doesn’t say why.

Pfizer has said that there is no warning concerning alcohol consumption given to those receiving the vaccine it has developed with BioNTech. AstraZeneca, which has signed a deal to collaborate with the Sputnik V project, didn’t respond to a request for information on alcohol and vaccination.



https://www.newscientist.com/article/2262654-should-you-avoid-alcohol-when-getting-a-coronavirus-vaccine/#ixzz6h7CFVQ51

Workhorse Steroid's Still the Go-To Standard for COVID

 One year into the COVID-19 pandemic, hospital physicians say the best and most reliable drug for the illness is cheap, familiar, and has all the glamour of a Bayer aspirin.

It's dexamethasone, the steroid workhorse that's been around longer than most of the doctors who prescribe it.

"I love the irony that one of the cheapest medications that exists is one of the only ones that has shown any benefit," said University of California San Francisco hospitalist Charlie Wray, DO, in an interview. "We know the side effect profiles, we know the risks, and we know that the benefit could be saving a life."

Physicians say dexamethasone shows more benefit than drugs that have made a splash in the media such as remdesivir and convalescent plasma. But warn about dexamethasone's infamous side effects, which can be especially common in the older patients most prone to severe cases of COVID-19, and they urge caution about its use in patients who don't yet need oxygen.

Corticosteroids weren't always the hot drug for COVID. In the early days of the pandemic, "there was a big outpouring of 'don't use steroids' because there was literature from SARS and MERS that found patients who got steroids had higher viral loads," recalled critical care pharmacist Michael Sirimaturos, PharmD, of Houston Methodist Hospital. "In those coronavirus disorders, the steroids seemed to make the virus replicate more or delay the immune system's response to clear it."

His hospital followed the steroid guidance when it saw its first case on March 13, Sirimaturos said. "But then we started getting more and more patients and realizing they weren't getting any better. They were in the hospital for 2-3 weeks, and they started showing classic signs of acute respiratory distress syndrome."

Steroids had previously shown value in treatment for ARDS, he said, while other drugs like hydroxychloroquine weren't working, and the patients "looked terrible and weren't getting better." So the hospital changed course and started administering steroids and saw a significant impact: "Wow, the patients are doing better, the chest x-rays are looking better, their oxygen saturations are getting better."

An influential study in the New England Journal of Medicine in July supported use of dexamethasone. It found that 28-day mortality was reduced among patients on oxygen alone (23.3% vs 26.2% with standard care; RR 0.82; 95% CI 0.72-0.94) or a mechanical ventilator (29.3% vs 41.4%; RR 0.64; 95% CI 0.51-0.81).

On the other hand, death rates were higher when the drug was given before oxygen supplementation relative to standard care (17.8% vs 14.0%; RR 1.19; 95% CI 0.91-1.55).

"If you look at the treatments we have for COVID -- remdesivir, convalescent plasma, dexamethasone -- the only one shown to have a mortality benefit is dexamethasone" said Wray, the San Francisco hospitalist. "Convalescent plasma doesn't really work. Remdesivir shortens hospital length of stay, which is a nice thing to do," but doesn't affect mortality.

Research released in September found that other steroids, too, are beneficial in COVID. The National Institutes of Health's guidelines about steroids and COVID notes that "if dexamethasone is not available, alternative glucocorticoids such as prednisone, methylprednisolone, or hydrocortisone can be used."

Dexamethasone has been around for more than 60 years. Unlike other COVID treatments, it is inexpensive, although its cost has reportedly more than doubled in recent months, with one analyst calling this worrisome while also noting that the price is historically volatile.

There have been shortages of specific doses of dexamethasone but they haven't been significant enough to affect its overall availability, said Michael Ganio, PharmD, senior director of Pharmacy Practice and Quality at the American Society of Hospital Pharmacists, in an interview. "The shortages shouldn't be impacting care, although they may make operations difficult if you only have access to the larger amounts or you have to draw up a dose from multiple vials."

It can be tricky to figure out when to start and stop dexamethasone or other steroids in COVID. If you start them too early, they'll dampen the immune system when it needs to be strong, pharmacist Sirimaturos said. Start them too late and you may miss the period when the body is overreacting and causing havoc in the lungs.

But physicians agree that the drug is helpful and in general should be given when patients are on supplemental oxygen or earlier in some cases. "If you've got a very sick individual in front of you, you should have a low threshold to start steroids if the patient is deteriorating," Wray said. "If you're ever in doubt, I would give steroids."

New Orleans pulmonologist Joshua Denson, MD, agreed. "Outside of the context of [supplemental] oxygen, I'd be trying to find another indication to support giving them," he said in an interview. Even then, "you'd have to have a pretty strong justification."

Some patients with underlying disorders such asthma and COPD may already be on steroids before they need oxygen therapy, and they should get their doses increased, Denson said. But Sirimaturos, the pharmacist, cautioned that COVID can trigger reactivation of herpes simplex virus and cytomegalovirus, and steroids must be used carefully in patients with those disorders.

At the University of Minnesota, the protocol is to start dexamethasone in COVID-positive patients who are hypoxic (<90% on room air) and stop it when the patient is no longer hypoxic or at discharge, said hospitalist Benji Mathews, MD. "Continuing dexamethasone in COVID-19 patients who are not hypoxic increases their risk," he said.

The NIH says dexamethasone "should be continued for up to 10 days or until hospital discharge, whichever comes first."

Sirimaturos agreed that it's important to not keep patients on steroids indefinitely. "You should see a benefit within the first 3-4 days. Maybe reevaluate 4-5 days in. Just because steroids are good doesn't mean they should be on them forever. I do see that physicians like to keep patients on them longer than necessary."

Dexamethasone is notorious for its behavioral side effects, as the nation learned when President Trump insisted on taking a limousine ride after getting it during his bout with COVID. "Steroid-induced psychosis or altered mental status is quite common, especially in older adults," said New Orleans pulmonologist Denson. "If it occurs, you can try reducing the dose and making their daily routine as similar to normal as possible – awake in daytime and asleep at nighttime. You can try other medications as needed as that might help."

Wray advised colleagues to "be aware that steroid-induced psychosis can look a lot like hospital delirium, an extremely common entity we see in patients who are hospitalized and are very sick -- where people become hyperactive, unable to sleep, and with altered mental status. Teasing these two phenomena out from one another can be difficult."

In either case, he said, "we do our best to reorient the patient to where they are and what's going on. If possible, we like to have family at bedside to help reorient them, as well. But that's not really possible right now. Finally, we do small things like giving steroids in the morning so that they don't interfere with sleep patterns too much."

What's next? Multiple studies are underway or planned to examine steroids as treatments for COVID. One study in Chile, which is expected to be completed this month, examines whether treatment with prednisone will help patients with mild disease avoid exacerbation.

For now, "steroids are the best thing we have," pulmonologist Denson said, "and that's pretty weak sauce."

https://www.medpagetoday.com/infectiousdisease/covid19/90327

Virus Relief Bill Held Up by GOP Bid to Limit Fed's Lending Power

 A Republican push to curtail the Federal Reserve's emergency lending powers kept congressional leaders from completing a $900 billion coronavirus relief package for a second day Saturday, with the parties digging in over the late-emerging dispute.

Congressional leaders agreed to the contours of the sweeping relief package earlier this week. They have maintained for days that they were close to finalizing its details, if the rift over the Fed provision from Sen. Pat Toomey (R., Pa.) can be resolved.

"Sen. Toomey's legislation is the only significant hurdle to completing an agreement," Senate Minority Leader Chuck Schumer (D., N.Y.) said on the Senate floor Saturday. "It's about tying the hands of the next Treasury secretary and the next Fed chairman in a true emergency."

The relief package under discussion is expected to include $300 a week in enhanced unemployment benefits, a second round of stimulus checks and funding for schools, health-care providers, vaccine distribution and small businesses. Negotiations accelerated this week after congressional leaders agreed to drop two provisions: funding for hard-hit state and local governments, which Democrats and some Republicans had sought, as well as liability protections for businesses and other entities operating during the pandemic, a top GOP priority.

Congressional leaders expect to bundle the coronavirus aid package with a full-year spending bill needed to keep the government running after its current funding expires at 12:01 a.m. Monday.

House Speaker Nancy Pelosi (D., Calif.) told House Democrats on a conference call Saturday that "we're right within reach" on an agreement, though the disagreement on emergency lending powers persisted.

Senate Majority Leader Mitch McConnell (R., Ky) told Senate Republicans on a call Saturday afternoon that he would back Mr. Toomey's position, according to someone familiar with the discussion.

Mr. Toomey has pushed to insert a measure that would restrict the Federal Reserve's ability to establish the types of emergency lending programs that it authorized in March to curb an emerging financial panic. That step would go beyond an earlier proposal to revoke $429 billion provided to the Treasury to backstop losses in the Fed lending programs.

Treasury Secretary Steven Mnuchin last month declined to allow the programs to continue after Dec. 31, saying he didn't think it was legally allowed. A nonpartisan congressional research arm disputed that interpretation on Thursday.

In March, the Federal Reserve announced lending programs to keep credit flowing to large companies and cities and states. Days later, Congress provided $454 billion for the Treasury to cover losses in Fed lending programs. Credit markets rebounded strongly and the Fed ultimately purchased fewer than $30 billion in loans and other assets.

Mr. Toomey has insisted that the Fed be prevented from reviving those programs without explicit congressional approval. His proposal would bar the Fed and Treasury from independently establishing any program that sought to purchase debts of businesses, cities or states, as the Fed has done this year.

"They have achieved their purpose. They should come to an end, they should not be restarted and a replica should not be created. That's all, " Mr. Toomey said on the Senate floor Saturday.

Mr. Toomey met with Mr. Schumer on Saturday afternoon. "I think we should be able to get a deal done," he said as he left Mr. Schumer's office.

https://www.marketscreener.com/news/latest/Virus-Relief-Bill-Held-Up-by-GOP-Bid-to-Limit-Fed-s-Lending-Powers-4th-Update--32051496/